Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 10Neoplasms 8Lymphoma 7Carcinoma, Non-Small-Cell Lung 7Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms, Plasma Cell 4Advanced Solid Tumors 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Lung Neoplasms 3Leukemia 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Solid Tumors 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × Panobinostat × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡